Squarepoint’s Oncolytics Biotech ONCY Stock Holding History

Squarepoint’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-11,725	Closed	-$25.6K	–	4353
2023 Q3	$25.6K	Buy	+11,725	New	+$28.6K	﹤0.01%	3685
2021 Q2	–	Sell	-11,650	Closed	-$44K	–	3570
2021 Q1	$44K	Buy	+11,650	New	+$34.8K	﹤0.01%	2993

Other funds holding ONCY

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ARC

Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's ONCY Position: Q4 2023 in Review

Squarepoint sold out of Oncolytics Biotech (ONCY) in Q4 2023, closing a stake of 11,725 shares — an estimated $25.6K sold.

Squarepoint first reported a position in ONCY in Q1 2021 and held it in 2 quarters. The position peaked at $44K in Q1 2021. 44 funds tracked by Wall St. Rank hold ONCY as of Q4 2023.

Squarepoint reported no remaining Oncolytics Biotech position as of Q4 2023 after selling out during the quarter.
Squarepoint sold 11,725 Oncolytics Biotech shares in Q4 2023, an estimated $25.6K.
Squarepoint first reported a position in Oncolytics Biotech in Q1 2021 and held it in 2 quarters.
Squarepoint's Oncolytics Biotech position peaked at $44K in Q1 2021.
44 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2023.

Based on Squarepoint's 13F filing for Q4 2023, filed 14 Feb 2024.